Monday, January 02, 2023 4:51:35 PM
What Pfizer says about "real scientists" vs what real scientists say pic.twitter.com/ZF7uOS4uJQ
— Michael Lin, MD PhD 🧬 (@michaelzlin) December 8, 2022
Good news for a Need for Bucillamine : ) I hope anyway lol...
In normal times the FDA is fairly strict about matching approvals to actual data, but FDA is now reluctant to pull EUA if the drugs remain useful for those truly in need, e.g. even vaxxed elderly need Paxlovid.
The solution should be to require updated trials to keep EUA
In normal times the FDA is fairly strict about matching approvals to actual data, but FDA is now reluctant to pull EUA if the drugs remain useful for those truly in need, e.g. even vaxxed elderly need Paxlovid.
— Michael Lin, MD PhD 🧬 (@michaelzlin) December 8, 2022
The solution should be to require updated trials to keep EUA
Ps...
The underlying issue is our regulatory systems rely on good faith and people not gaming the system, but big pharma have become cynical game players.
— Michael Lin, MD PhD 🧬 (@michaelzlin) December 8, 2022
Specifically, FDA is obligated to evaluate data that sponsors submit as part of an approval procedure (with their PDUFA fee)...
Almost forgot this one...
The study shows increased likelihood of hospitalization, cardiovascular effects, blood disorders, diabetes, fatigue, kidney damage, mental health effects, musculoskeletal damage, neurological deficits, and pulmonary damage with each COVID-19 infection https://t.co/Sw3hY6GzoM
— Harvard Medical School (@harvardmed) December 31, 2022
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
